Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes
© Matsumura et al; licensee BioMed Central Ltd. 2011
Received: 19 November 2010
Accepted: 25 March 2011
Published: 25 March 2011
The number of patients with non-HIV Pneumocystis pneumonia (PCP) is increasing with widespread immunosuppressive treatment. We investigated the clinical characteristics of non-HIV PCP and its association with microbiological genotypes.
Between January 2005 and March 2010, all patients in 2 university hospitals who had been diagnosed with PCP by PCR were enrolled in this study. Retrospective chart review of patients, microbiological genotypes, and association with 30-day mortality were examined.
Of the 82 adult patients investigated, 50 patients (61%) had inflammatory diseases, 17 (21%) had solid malignancies, 12 (15%) had hematological malignancies, and 6 (7%) had received transplantations. All patients received immunosuppressive agents or antitumor chemotherapeutic drugs. Plasma (1→3) β-D-glucan levels were elevated in 80% of patients, and were significantly reduced after treatment in both survivors and non-survivors. However, β-D-glucan increased in 18% of survivors and was normal in only 33% after treatment. Concomitant invasive pulmonary aspergillosis was detected in 5 patients. Fifty-six respiratory samples were stored for genotyping. A dihydropteroate synthase mutation associated with trimethoprim-sulfamethoxazole resistance was found in only 1 of the 53 patients. The most prevalent genotype of mitochondrial large-subunit rRNA was genotype 1, followed by genotype 4. The most prevalent genotype of internal transcribed spacers of the nuclear rRNA operon was Eb, followed by Eg and Bi. Thirty-day mortality was 24%, in which logistic regression analysis revealed association with serum albumin and mechanical ventilation, but no association with genotypes.
In non-HIV PCP, poorer general and respiratory conditions at diagnosis were independent predictors of mortality. β-D-glucan may not be useful for monitoring the response to treatment, and genotypes were not associated with mortality.
Pneumocystis jirovecii pneumonia (PCP) is widely known as an opportunistic infection in human immunodeficiency virus (HIV)-infected patients. The introduction of chemoprophylaxis and highly active antiretroviral therapy has reduced the incidence of HIV PCP in recent years [1, 2]. In contrast, PCP in non-HIV immunocompromised patients is increasing as the number of patients receiving transplantation, immunosuppressive therapy, and antitumor chemotherapeutic agents continues to grow .
For years, the standard method for laboratory diagnosis of PCP was the visualization of P. jirovecii by microscopy in bronchoalveolar lavage (BAL) fluid or induced sputum. It is known that non-HIV patients often develop PCP with a lower parasite burden than HIV patients , which may result in a false negative microscopic determination . Although immunofluorescent antibody stain has improved the sensitivity compared to Gomori methenamine silver or Giemsa stains , a more sensitive polymerase chain reaction (PCR) test has recently been employed [6, 7]. However, being PCR-positive does not necessarily indicate a diagnosis of PCP. Pneumocystis colonization, defined as detection of the organism or its DNA without signs or symptoms of pneumonia, has been reported irrespective of immunosuppressive conditions . Furthermore, PCR-positive patients with pulmonary infiltrates diagnosed as a pneumonia other than PCP were also considered to have colonization of P. jirovecii [4, 9]. Without microscopy-positive patients, differentiation between PCP and colonization can only be done by clinical diagnosis. For adjunctive diagnosis, (1→3) β-D-glucan tests have also been used [10–12]. Because most of the studies on non-HIV PCP have been based on microscopic diagnosis, its clinical characteristics, including the β-D glucan test in PCR-diagnosed non-HIV PCP patients, are still not well described.
Strain analysis of P. jirovecii had been conducted by molecular genotyping based on nucleotide sequence variations because of the inability to culture. Studies mainly on HIV PCP have targeted the mitochondrial large-subunit rRNA (mt LSU rRNA) and internal transcribed spacer (ITS) regions of the nuclear rRNA operon, and the dihydropteroate synthase (DHPS) gene . Mt LSU rRNA and ITS have been used to analyze the cluster of PCP, the route of transmission, and association of severity [13, 14]. The DHPS mutation is thought to be associated with failure of treatment and prophylaxis [15, 16]. However, molecular epidemiology and the clinical relationship with non-HIV PCP have been described in only small-scale studies.
In this study, we describe the clinical characteristics of non-HIV PCP based on PCR diagnosis. This includes the underlying conditions, laboratory findings such as β-D glucan tests, complications, and the association of prognostic factors. We also evaluate the clinical significance of microbiological genotypes.
Study site and population
We retrospectively reviewed all consecutive non-HIV patients tested by pneumocystis PCR analysis between January 2005 and March 2010 at 2 tertiary care university hospitals, Kyoto University Hospital and Nagoya University Hospital, in Japan. After reviewing the medical records for all patients tested, diagnoses of PCP were made if the patients met all of the following criteria: new ground glass opacities in chest computed tomography, positive PCR targeting of mt LSU rRNA, and clinical suspicion of PCP by an attending physician defined as presumptive treatment for PCP. Presumptive treatment occurred when PCR results were pending and continued until resolution or death. Only patients with the first episode of PCP were included. If multiple samples were taken for a patient, the samples were taken in the following order: BAL fluid, sputum, and oral wash. The Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (E-356) and the Institutional Review Board of Nagoya University Graduate School of Medicine (641) approved this study and waived the need for obtaining informed consent from each patient.
Clinical information acquired by medical chart review included underlying diseases, immunosuppressive therapies during the previous month, PCP prophylaxis, clinical symptoms, laboratory values, Sequential Organ Failure Assessment (SOFA) score , anti-PCP treatment, complications, invasive fungal infections, and 30-day mortality. The daily dosage of corticosteroids was expressed as the prednisolone equivalent (1 mg of prednisolone equals 0.8 mg of methylprednisolone equals 1 mg of prednisone). Hypoxemia was defined as arterial PaO2 < 70 mm Hg in room air or a requirement for supplemental oxygen. Invasive fungal infection was diagnosed according to the European Organization for Research and Treatment of Cancer criteria .
Plasma β-D-glucan was measured with the β-glucan test WAKO (Wako Pure Chemical Industries; Tokyo, Japan). Plasma samples were collected before and after PCP treatment. The assay was performed as a clinical routine at our institution on the same day when the plasma was obtained.
PCR detection and genotyping
DNA was extracted using the QIAamp DNA mini kit (Qiagen; Hilden, Germany). Molecular detection of P. jirovecii was carried out by single round PCR amplification of mt LSU rRNA .
DHPS genotypes were determined by nested PCR and RFLP analysis , based on codon 55/57 mutations: wild type (Thr/Pro), single mutant (Ala/Pro or Thr/Ser), and double mutant (Ala/Ser). Mt LSU rRNA genotypes were determined by direct sequencing at nucleotides 85 and 248: genotype 1 (C/C), 2 (A/C), 3 (T/C), 4 (C/T), and 5 (C/T). When mixed genotypes were suspected, amplification products were cloned and then 5 clones were randomly selected and sequenced. ITS regions were amplified by nested PCR , and the 5 clones were analyzed using scores described elsewhere [22–25]. If multiple haplotypes (combinations of ITS1 and ITS2 types) were detected from 1 sample, mixed-type were considered only when both haplotypes were detected in at least 1 single-type sample.
To investigate the relationship with severity or outcome, we compared each genotype with hypoxemia, SOFA score, mechanical ventilation, and 30-day mortality.
Categorical variables were compared using Fisher's exact test. Continuous variables were compared using the Mann-Whitney U test. β-D-glucan values under the commercial upper limit of the normal value of 11 pg/mL were considered to be 1.1 pg/mL when comparing the values before and after treatment. To determine the association of independent variables with 30-day mortality, a stepwise logistic regression analysis was performed. Variables with a P-value of less than 0.10 on univariate analyses were included in the multiple regression model with step forward analysis. P < 0.05 was considered statistically significant. We performed our statistical analyses using R version 2.9.2 (R foundation for Statistical Computing; http://www.r-project.org).
Of 82 PCP patients, 64 patients (39 males) were from Kyoto University Hospital and 18 (12 males) were from Nagoya University Hospital. The median age was 64 years (range, 19-82 years). Respiratory samples that were obtained for PCR were sputum in 41 patients, BAL fluid in 35, and oral wash in 6. Sputum or oral wash were simultaneously obtained in 9 patients who underwent bronchoscopy, which were all PCR-positive. Some of the samples underwent microscopic analysis using the Gomori methenamine silver stain. Eight of 33 (24%) samples of BAL fluid and 2 of 31 (6%) of sputum were microscopically positive.
Patient demographics at diagnosis of pneumocystis pneumonia in 82 patients
Age, years (range)
Systemic lupus erythematosus
Pemphigus or pemphigoid
Pulmonary disease other than lung cancer
Chronic obstructive pulmonary disease
Current or ex-smoker
(n = 82)
(n = 62)
(n = 20)
Daily dose, mg
Less than 10 mg/day
Total duration, days
Less than 1 month
Lower respiratory symptoms
PaO2/FiO2 ratio (n = 50)
C-reactive protein, mg/dL
Blood urea nitrogen, mg/dL
Total bilirubin, mg/dL
Lactate dehydrogenase, IU/L
LDH > upper limit of normal value
β-D-glucan (n = 81), pg/mL
β-D-glucan (n = 81) >11 pg/mL
Adjunctive steroid therapy
Invasive pulmonary aspergillosis
Clinical features associated with 30-day mortality in multivariate logistic regression analysis
Immunosuppressive agents other than corticosteroids
Lymphocyte, per 100/mm3
Albumin, per 0.1 mg/dL
Lactate dehydrogenase, per 100 IU/L
Invasive pulmonary aspergillosis
Genotypes of Pneumocystis jirovecii in 56 patients
Total numbers tested
mt LSU rRNA
Ai, Ce, "H"r, Ir, Iu3, U1e
PCP is diagnosed by identifying P. jiroveci in respiratory specimens, but it is often difficult to obtain BAL samples in non-HIV patients with severe and rapidly progressive disease [3, 26]. Highly sensitive PCR allowed us to detect P. jirovecii in samples with negative direct examination tests and in non-invasive samples, such as induced sputum  or oral wash . Although PCR for P. jiroveci can be positive in asymptomatic colonized patients, PCP therapy is recommended in patients with clinical suspicion of PCP and positive PCR results . According to these backgrounds, our diagnostic criteria included presumptive treatment due to strong suspicion by a clinician for PCP, in addition to the PCR and imaging studies. We excluded 2 patients for whom treatment was initiated after the PCR result. Because it usually takes 3 to 10 days to get PCR results in our practice, a delay in treatment would have some effect over outcomes. PCR-positive patients without treatment had clinical diagnoses other than PCP. PCR-negative patients irrespective of receipt of treatment were also excluded, because PCR in non-HIV patients has a quite high negative predictive value .
The main risk factors for PCP are deficiencies in cellular immunity and the use of immunosuppressive agents, especially corticosteroids. Similar to previous reports [28, 29], even with a low dose or short duration of corticosteroids, our patients developed PCP. In addition to corticosteroids, the introduction of high-intensity immunosuppressive regimens such as anti-tumor necrosis factor-α drugs has increased in inflammatory diseases. Post-marketing surveillance of anti-tumor necrosis factor-α drugs revealed a much higher incidence of PCP in Japan than in the US . Six PCP patients (7.3%) in this study received anti-tumor necrosis factor-α drugs. Reported attack rates of PCP in non-HIV patients not receiving prophylaxis are highest in hematological malignancies and transplantation [28, 31]. In our study, almost two-thirds of PCP patients had inflammatory diseases and fewer patients had hematological malignancies or transplantation. This may be because PCP prophylaxis is common in hematological malignancies or transplantation, but not in inflammatory diseases, and the number of patients with inflammatory diseases in the general population is larger.
Elevated serum LDH levels have been noted in patients with PCP  but were not specific. β-D-glucan was reported to be elevated in 96% of 111 HIV patients with microscopic diagnosis of PCP  and 78% of 18 non-HIV patients with a PCR-based diagnosis . The latter value is almost the same as our result (80%). Some reports have found high β-D-glucan to be a predictor of death [32, 33], while others have not [34, 35]. The β-D-glucan value did not differ between survivors and non-survivors in our study (Table 2). In a study of 21 non-HIV PCP patients of whom 2 died within 30 days, it was reported that β-D-glucan a median of 3 days after treatment had significantly decreased . In our study, β-D-glucan in survivors and non-survivors was separately analyzed, and in both groups it was significantly reduced after treatment. However, normalization occurred only in 33% of survivors, and in some patients from both groups, β-D-glucan increased after treatment. In a report of 42 HIV PCP patients, normalization after 3 weeks of successful treatment occurred in only 17% of patients, and elevated levels were found in 21% of patients . These results suggest that a decrease of β-D-glucan simply corresponds with treatment, but does not predict treatment response. Since β-D-glucan is a cell wall component of P. jirovecii, the level of β-D-glucan may reflect the organism burden directly, not the severity of PCP. Limper et al. demonstrated that mortality was not associated with organism burden, but rather the number of neutrophils in the lower respiratory tract . When β-D-glucan increases compared to the level before treatment, it may not indicate deterioration of PCP.
Non-HIV immunocompromised patients often develop invasive aspergillosis . We found 5 patients who developed probable aspergillosis. Although Aspergillus has not been generally recognized as a co-pathogen of P. jirovecii, it is possible that it is because both PCP and aspergillosis develop with the use of immunosuppressive agents [28, 29, 36]. Aspergillosis was found to be a significant predictor of death in univariate analysis and almost reached significance in multivariate analysis. Aspergillosis should be considered when there is a poor treatment response to PCP.
Twenty-four percent of our patients died, which is similar to the reported mortality rate of 19 to 40% [1, 29, 37]. We found that albumin and mechanical ventilation were independent predictors. These factors have been reported previously [29, 37].
The epidemiology of PCP in large numbers of non-HIV patients separate to that of HIV patients has never been reported. From a previous small Japanese study, 2 of 8 non-HIV patients had the DHPS mutation . Our patients had a very low rate of DHPS mutations, which cannot be generalized for non-HIV patients, because mutant rates in HIV patients vary widely (3% to 69%) . In addition, the prophylactic use of TMP-SMX may be associated with the emergence of DHPS mutant strains in HIV patients . One possible explanation of the low rate of DHPS mutants in our patients is the rarity of prophylaxis.
There is little information about the clinical background of the mt LSU rRNA genotypes. The only study describing the clinical relationships in 53 HIV and 7 non-HIV patients found no association . We also found no association in our patients. The largest study that has investigated the genotypes of non-HIV PCP included 17 patients from 3 PCP clusters in Sweden . Genotypes 1, 2, 3, and mixed-types were found in 5, 2, 3, and 7 patients, respectively. Other studies for HIV PCP, non-HIV PCP, and non-HIV patients without pneumonia found that genotypes 1 or 2 were the most prevalent, and genotype 4 was the least prevalent [20, 40, 42–45]. Genotype 1 was the most prevalent in our study, which is consistent with those reports. However, it is inconsistent with regard to genotype 4, which was the second prevalent type in this study.
The clinical correlation with the ITS genotypes has been conflicting [14, 46]. We did not find a correlation. Some studies have focused on the epidemiology of the ITS genotype in non-HIV PCP [40, 47], but the number of patients was less than 10. We investigated 31 patients and found Eb, Eg, and Bi from multiple patients as a single haplotype. Mixed infections were detected in 16%. Genotypes Eb, Eg, Bi, and Ne are reported to be common in HIV PCP, and mixed infections are reported in 5-79% [20, 22–24, 40, 48]. Those previous studies overestimated the mixed infections, because many of the less common haplotypes resulted from in vitro recombinations of globally common ITS haplotypes present in the same sample .
Our study is retrospective, and it has several limitations. One limitation is the heterogeneity of the respiratory sample and underlying clinical conditions. More than half of the samples obtained for PCR were not BAL fluid, and not all of the samples underwent microscopic analysis. Of the PCR-diagnosed PCP, microscopic examinations were positive only in 24% of BAL fluid and in 6% of sputum. One possible reason for the low positive rate is that Gomori methenamine silver stain has less sensitivity than an immunofluorescent antibody stain . The underlying clinical conditions and stage of disease might have varied, which could be uncontrolled confounders of the cause of death. Another limitation is that our study may still lack the statistical power to determine a clinical relationship between genotypes and outcome, although it is the largest to date on genotypes of non-HIV PCP.
This is the largest study to date that describes the clinical characteristics of non-HIV PCP based on PCR diagnosis. We found that inflammatory disease was the most common underlying condition, and all of the patients received immunosuppressive agents or chemotherapeutic agents. β-D-glucan may not be useful for monitoring the response to treatment. Predictors of death were similar to previous reports, except that invasive pulmonary aspergillosis was a predictor of death in univariate analysis. During treatment, invasive pulmonary aspergillosis should be noted carefully. Microbiological genotypes of non-HIV PCP were also described in the largest population, in which there were few DHPS mutation and no relationship with the clinical characteristics. The prevalence of ITS and mt LSU rRNA genotypes in non-HIV patients did not seem to be significantly different when compared to reports for HIV patients. Further investigation is needed to evaluate microbiological genotypes from a clinical point of view.
Financial support: This work was supported by the Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine.
- Mansharamani N, Garland R, Delaney D, Koziel H: Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000, 118: 704-711.View ArticlePubMedGoogle Scholar
- Kelley C, Checkley W, Mannino D, Franco-Paredes C, Del Rio C, Holguin F: Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005). Chest. 2009, 136: 190-197.View ArticlePubMedGoogle Scholar
- Limper A, Offord K, Smith T, Martin Wn: Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989, 140: 1204-1209.View ArticlePubMedGoogle Scholar
- Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J: Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009, 135: 655-661.View ArticlePubMedGoogle Scholar
- Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, Artymyshyn RL, Katanik MT, Weinstein MP: Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol. 2004, 42: 3333-3335.View ArticlePubMedPubMed CentralGoogle Scholar
- Krajicek BJ, Thomas CF, Limper AH: Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009, 30: 265-278.View ArticlePubMedGoogle Scholar
- Thomas CJ, Limper A: Pneumocystis pneumonia. N Engl J Med. 2004, 350: 2487-2498.View ArticlePubMedGoogle Scholar
- Morris A, Wei K, Afshar K, Huang L: Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis. 2008, 197: 10-17.View ArticlePubMedGoogle Scholar
- Jiancheng W, Minjun H, Yi-jun A, Lan S, Zengzhu G, Jianrong S, Xixiong K: Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis. 2009, 64: 396-401.View ArticlePubMedGoogle Scholar
- Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, Honda M, Gatanaga H, Teruya K, Kikuchi Y, et al: Serum (1→3)-β-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009, 49: 1128-1131.View ArticlePubMedGoogle Scholar
- Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, Ishizaka A: Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007, 131: 1173-1180.View ArticlePubMedGoogle Scholar
- Shimizu Y, Sunaga N, Dobashi K, Fueki M, Fueki N, Makino S, Mori M: Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009, 9: 47-View ArticlePubMedPubMed CentralGoogle Scholar
- Beard C, Roux P, Nevez G, Hauser P, Kovacs J, Unnasch T, Lundgren B: Strain typing methods and molecular epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004, 10: 1729-1735.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller R, Wakefield A: Pneumocystis carinii genotypes and severity of pneumonia. Lancet. 1999, 353: 2039-2040.View ArticlePubMedGoogle Scholar
- Helweg-Larsen J, Benfield T, Eugen-Olsen J, Lundgren J, Lundgren B: Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999, 354: 1347-1351.View ArticlePubMedGoogle Scholar
- Alvarez-Martínez M, Moreno A, Miró J, Valls M, Rivas P, de Lazzari E, Sued O, Benito N, Domingo P, Ribera E, et al: Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis. 2008, 62: 34-43.View ArticlePubMedGoogle Scholar
- Vincent J, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter P, Sprung C, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998, 26: 1793-1800.View ArticlePubMedGoogle Scholar
- De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T, Pappas P, Maertens J, Lortholary O, Kauffman C, et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008, 46: 1813-1821.View ArticlePubMedPubMed CentralGoogle Scholar
- Wakefield A, Pixley F, Banerji S, Sinclair K, Miller R, Moxon E, Hopkin J: Detection of Pneumocystis carinii with DNA amplification. Lancet. 1990, 336: 451-453.View ArticlePubMedGoogle Scholar
- Esteves F, Montes-Cano M, de la Horra C, Costa M, Calderón E, Antunes F, Matos O: Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clin Microbiol Infect. 2008, 14: 356-362.View ArticlePubMedGoogle Scholar
- Beser J, Hagblom P, Fernandez V: Frequent in vitro recombination in internal transcribed spacers 1 and 2 during genotyping of Pneumocystis jirovecii. J Clin Microbiol. 2007, 45: 881-886.View ArticlePubMedPubMed CentralGoogle Scholar
- Hosoya N, Takahashi T, Wada M, Endo T, Nakamura T, Sakashita H, Kimura K, Ohnishi K, Nakamura Y, Mizuochi T, et al: Genotyping of Pneumocystis carinii f. sp. hominis isolates in Japan based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. Microbiol Immunol. 2000, 44: 591-596.View ArticlePubMedGoogle Scholar
- Totet A, Pautard J, Raccurt C, Roux P, Nevez G: Genotypes at the internal transcribed spacers of the nuclear rRNA operon of Pneumocystis jiroveci in nonimmunosuppressed infants without severe pneumonia. J Clin Microbiol. 2003, 41: 1173-1180.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee C, Helweg-Larsen J, Tang X, Jin S, Li B, Bartlett M, Lu J, Lundgren B, Lundgren J, Olsson M, et al: Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol. 1998, 36: 734-741.PubMedPubMed CentralGoogle Scholar
- Siripattanapipong S, Worapong J, Mungthin M, Leelayoova S, Tan-ariya P: Genotypic study of Pneumocystis jirovecii in human immunodeficiency virus-positive patients in Thailand. J Clin Microbiol. 2005, 43: 2104-2110.View ArticlePubMedPubMed CentralGoogle Scholar
- Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL: Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984, 100: 663-671.View ArticlePubMedGoogle Scholar
- Helweg-Larsen J, Jensen J, Benfield T, Svendsen U, Lundgren J, Lundgren B: Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 1998, 36: 2068-2072.PubMedPubMed CentralGoogle Scholar
- Yale S, Limper A: Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996, 71: 5-13.View ArticlePubMedGoogle Scholar
- Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, De Gentile L, Gandji J, Guimard Y, Lacroix C, et al: Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002, 21: 523-531.View ArticlePubMedGoogle Scholar
- Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, et al: Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009, 61: 305-312.View ArticlePubMedGoogle Scholar
- Rodriguez M, Fishman J: Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004, 17: 770-782.View ArticlePubMedPubMed CentralGoogle Scholar
- Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M: Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006, 16: 282-288.View ArticlePubMedGoogle Scholar
- Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K, Adachi T, Tanaka Y: Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology (Oxford). 2004, 43: 479-485.View ArticleGoogle Scholar
- Held J, Koch M, Reischl U, Danner T, Serr A: Serum (1→3)-β-D-glucan measurement as early indicator for Pneumocystis jiroveciipneumonia and evaluation of its prognostic value. Clin Microbiol Infect. Google Scholar
- de Boer MG, Gelinck LB, van Zelst BD, van de Sande WW, Willems LN, van Dissel JT, de Jonge R, Kroon FP: β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative Patients: A prospective study. J Infect. 2010, 62: 93-100.View ArticlePubMedGoogle Scholar
- Segal BH, Walsh TJ: Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006, 173: 707-717.View ArticlePubMedGoogle Scholar
- Aoki Y, Iwamoto M, Kamata Y, Nagashima T, Yoshio T, Okazaki H, Minota S: Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009, 29: 1327-1330.View ArticlePubMedGoogle Scholar
- Takahashi T, Hosoya N, Endo T, Nakamura T, Sakashita H, Kimura K, Ohnishi K, Nakamura Y, Iwamoto A: Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol. 2000, 38: 3161-3164.PubMedPubMed CentralGoogle Scholar
- Kazanjian P, Armstrong W, Hossler P, Burman W, Richardson J, Lee C, Crane L, Katz J, Meshnick S: Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis. 2000, 182: 551-557.View ArticlePubMedGoogle Scholar
- van Hal S, Gilgado F, Doyle T, Barratt J, Stark D, Meyer W, Harkness J: Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes. J Clin Microbiol. 2009, 47: 1818-1823.View ArticlePubMedPubMed CentralGoogle Scholar
- Olsson M, Eriksson B, Elvin K, Strandberg M, Wahlgren M: Genotypes of clustered cases of Pneumocystis carinii pneumonia. Scand J Infect Dis. 2001, 33: 285-289.View ArticlePubMedGoogle Scholar
- Montes-Cano M, de la Horra C, Martin-Juan J, Varela J, Torronteras R, Respaldiza N, Medrano F, Calderón E: Pneumocystis jiroveci genotypes in the Spanish population. Clin Infect Dis. 2004, 39: 123-128.View ArticlePubMedGoogle Scholar
- Miller RF, Lindley AR, Copas A, Ambrose HE, Davies RJ, Wakefield AE: Genotypic variation in Pneumocystis jirovecii isolates in Britain. Thorax. 2005, 60: 679-682.View ArticlePubMedPubMed CentralGoogle Scholar
- Beard CB, Carter JL, Keely SP, Huang L, Pieniazek NJ, Moura IN, Roberts JM, Hightower AW, Bens MS, Freeman AR, et al: Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis. 2000, 6: 265-272.View ArticlePubMedPubMed CentralGoogle Scholar
- Beard CB, Fox MR, Lawrence GG, Guarner J, Hanzlick RL, Huang L, del Rio C, Rimland D, Duchin JS, Colley DG: Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: Epidemiological Implications. J Infect Dis. 2005, 192: 1815-1818.View ArticlePubMedGoogle Scholar
- Valerio A, Tronconi E, Mazza F, Fantoni G, Atzori C, Tartarone F, Duca P, Cargnel A: Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr. 2007, 45: 521-528.View ArticlePubMedGoogle Scholar
- Helweg-Larsen J, Tsolaki A, Miller R, Lundgren B, Wakefield A: Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM. 1998, 91: 813-820.View ArticlePubMedGoogle Scholar
- Robberts FJ, Liebowitz LD, Chalkley LJ: Genotyping and coalescent phylogenetic analysis of Pneumocystis jiroveci from South Africa. J Clin Microbiol. 2004, 42: 1505-1510.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/76/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.